<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1175">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04628143</url>
  </required_header>
  <id_info>
    <org_study_id>A108_01CVD2013</org_study_id>
    <nct_id>NCT04628143</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia</brief_title>
  <official_title>Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of CKD-314 (Nafabelltan)&#xD;
      compared to standard of care (SOC), with respect to clinical status assessed by a 7-point&#xD;
      ordinal scale in hospitalized adult patients diagnosed with COVID-19 pneumonia&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, Multi-center, Randomized Controlled, Phase 2 Clinical Trial to Evaluate the&#xD;
      Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed with COVID-19&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 20, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to clinical improvement</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Time to clinical improvement (TTCI) was defined as time (days) from randomization to a decline of 2 categories on the seven-category ordinal scale of clinical status or live discharge from the hospital, whichever came first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recovery</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Day of recovery is defined as the first day on which the subject satisfies one of the following: 1) Not hospitalized with resumption of normal activities; 2) Not hospitalized, but unable to resume normal activities; 3) Hospitalization, not requiring supplemental oxygen- no longer required ongoing medical care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with clinical improvement as defined by live discharge from hospital or a decline of 2 categories on the seven-category ordinal scale of clinical status</measure>
    <time_frame>Day 4, 7, 10, 14, 21 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with recovery as defined as the subject satisfies one of the following</measure>
    <time_frame>Day 4, 7, 10, 14, 21 and 28</time_frame>
    <description>1) Not hospitalized with resumption of normal activities; 2) Not hospitalized, but unable to resume normal activities; 3) Hospitalization, not requiring supplemental oxygen- no longer required ongoing medical care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clinical status assessed by 7-category ordinal scale</measure>
    <time_frame>Day 4, 7, 10, 14, 21 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in National Early Warning Score (NEWS)</measure>
    <time_frame>Day 4, 7, 10, 14, 21 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to National Early Warning Score (NEWS) of ≤ 2 which is maintained</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of non-invasive ventilation or high flow oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of non-invasive ventilation or high flow oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Proportion of patients of non-invasive ventilation or high flow oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of supplement oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of supplement oxygen use</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Proportion of patients of supplement oxygen use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use</measure>
    <time_frame>up to 28 days</time_frame>
    <description>Proportion of patients of invasive ventilation or extracorporeal membrane oxygenation (ECMO) use</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>28-Day mortality</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of Care Treatment for COVID-19 Infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nafamostat + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nafamostat mesylate on top of standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nafamostat Mesilate</intervention_name>
    <description>Administered intravenously as a continuous infusion</description>
    <arm_group_label>Nafamostat + Standard of Care</arm_group_label>
    <other_name>CKD-314</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women Aged ≥18 years&#xD;
&#xD;
          -  Hospitalized subjects who have confirmed COVID-19 infection and have evidence of&#xD;
             pneumonia:&#xD;
&#xD;
               -  COVID-19 infection: SARS-CoV-2 positive confirmed by RT-PCR&#xD;
&#xD;
                    -  Pneumonia: A reliable diagnosis of new lung infiltration on a chest CT scan&#xD;
                       or chest radiograph&#xD;
&#xD;
          -  Subjects within 72 hours after confirmed COVID-19 pneumonia&#xD;
&#xD;
          -  Subjects with a seven-category ordinal scale of clinical status of 4 (hospitalization,&#xD;
             requiring supplemental oxygen) or 5 (hospitalization, requiring nasal high-flow oxygen&#xD;
             therapy and/or noninvasive mechanical ventilation)&#xD;
&#xD;
          -  Subjects (or legally authorized representative) should be able to understand and agree&#xD;
             to comply with the clinical trial and to provide a written consent document prior to&#xD;
             initiation of any study procedure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a serious chronic disease&#xD;
&#xD;
          -  Subject requiring invasive mechanical ventilation at the time of screening&#xD;
&#xD;
          -  Subject with rapidly(within 3 days) deteriorating clinical condition according to the&#xD;
             investigator's opinion&#xD;
&#xD;
          -  Subject who have a record of HIV or AIDS&#xD;
&#xD;
          -  Subject taking corticosteroids[However, ① steroids being used for the treatment of&#xD;
             Corona 19 (eg, Dexamethasone, etc.), ② topical steroids,&#xD;
&#xD;
             ③ Patients who are administering inhaled steroids are not eligible for exclusion]&#xD;
&#xD;
          -  Subject taking immunosuppressants/immunomodulators&#xD;
&#xD;
          -  Subject with liver cirrhosis whose Child-Pugh score is B or C&#xD;
&#xD;
          -  Subject with hyperkalemia (K&gt; 5.1mmol/L)&#xD;
&#xD;
          -  Subject who have liver disease abnormalities with ALT or AST &gt; 5 times ULN&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 30 ml/min&#xD;
&#xD;
          -  QTc &gt;500ms&#xD;
&#xD;
          -  Subject who have hypersensitivity to the investigational drug&#xD;
&#xD;
          -  Pregnant or lactating females&#xD;
&#xD;
          -  Subject who are not appropriate for the study, as the investigator's opinion&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dongho Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea Cancer Center Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dongho Kim, MD</last_name>
    <phone>82-2-970-1298</phone>
    <email>kdh281920@gmail.com</email>
  </overall_contact>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 10, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nafamostat</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

